Ozempic + Mounjaro hit $71B revenue vs AI industry's $29B, with only 2% of patients reached
TansuYegen · x · 2026-10-19
A striking industry comparison: Ozempic + Mounjaro are on track for $71B in 2025 revenue — more than OpenAI and Anthropic combined at $29B. The poster argues the syringe, not a chatbot, is still the killer app: with only 2% of 800 million eligible patients currently served, expanding access would disrupt grocery carts, insurers, and consumer brands long before it touches your workflow.
Related event: GLP-1 Weight-Loss Drugs Still Out-Earn Top AI Labs by 1.3x(2 posts)→
More from AGI Musings
- Musk warns many will be 'one-shotted' by super-persuasive superintelligences — elonmusk · 2026-10-19
- Researcher: AI safety evals repeat crypto's classic 'I couldn't crack it' fallacy — davidmanheim · 2026-10-19
- One chart explains the AI economy: models commoditize while compute demand keeps surging — FinanceYF5 · 2026-10-19
- Schmidhuber to Give Free Public Lecture at Kyoto University on AI's Past, Present and Far Future — hardmaru · 2026-10-19
- 'Written with AI' tells you nothing — the disclosure that matters is how — indianbull88 · 2026-10-19
- "Today is the quiet period": dev on why AI progress never feels slow in hindsight — jam3scampbell · 2026-10-19